FDA to hold public hearing on psychedelic drugs as Trump-driven push gathers pace

The U.S. Food and Drug Administration will convene a public hearing on Monday to solicit input on the potential clinical applications of psychedelic substances, marking a recent escalation in efforts spearheaded by President Donald Trump's administration to expedite the advancement of these treatments for severe mental health disorders.

This hearing represents a component of a broader initiative initiated in April, wherein the President mandated the FDA to prioritize psychedelic drug programs for its priority-voucher scheme. The directive also called for cooperation between the FDA and the Drug Enforcement Administration to facilitate access for certain patients to experimental therapies under the federal Right to Try law, as well as to enhance cooperation with the Department of Veterans Affairs.

During the hearing, experts will deliberate on practical matters that could influence the testing and provision of psychedelic therapies, encompassing provider education and certification, patient assessment and surveillance, accessibility and reimbursement, clinic capacity, and the gathering of long-term safety data. The FDA explicitly stated that it is not soliciting opinions on individual drug applications, the classification of controlled substances, or the legalization of psychedelics.

Robert Barrow, CEO of Definium Therapeutics, which is creating an LSD-based therapy, expressed that the hearing presents an excellent chance for sustained discourse among regulators, healthcare professionals, and patients. He emphasized that regulators and the industry should treat psychedelics akin to conventional drug development, standard science, and standard medicine, rather than as an atypical category necessitating distinct treatment.

Just prior to the hearing, senior FDA officials, including Michael Davis, acting director of the agency's Center for Drug Evaluation and Research, published a paper in the New England Journal of Medicine presenting a framework for the development and approval of psychedelic drugs and indicating that the agency is seizing this opportunity in the treatment of challenging conditions such as major depressive disorder and PTSD.

The framework proposed that the FDA is prepared to entertain flexible trial designs to tackle issues such as functional unblinding, when a drug's discernible psychoactive effects disclose to participants which treatment they received. The FDA has indicated that developers could employ questionnaires, blinded central raters, and, in certain studies, lower doses or active comparators, which mimic some peripheral or subtle psychological effects, to address this issue, according to Jefferies analysts.

The administration's backing has ignited renewed investor interest in the sector, with industry executives asserting that it could enhance coordination between the FDA and the Drug Enforcement Administration and help alleviate regulatory delays, despite the fact that approved treatments were still likely to be years away.